Why These 2 Biotech Stocks May Be Bought Out Soon
In a new report, Stifel sees two biotech stocks with near-term catalysts that could make takeover candidates soon.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 266Is Celgene Stumped on Its Portfolio?
Celgene released mixed first-quarter results before the markets opened Thursday and shares were down in early trading.
What to Expect From Gilead Earnings
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) will report its first-quarter earnings Thursday after the markets close. Thomson Reuters has consensus estimates of $2.32 in earnings per share (EPS) on $6.92 billion in revenue. The first…
What to Expect From Celgene Earnings
ThinkstockCelgene Corp. (NASDAQ: CELG) is scheduled to release its first-quarter financial results before the markets open Thursday. Thomson Reuters has consensus estimates of $1.06 in earnings per share (EPS) on $2.11 billion in revenue.…
Will Schizophrenia and Bipolar Patients Trust Generic Abilify?
ThinkstockThe trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics can enter the market.…
Despite Currencies, Merck Delivers on Earnings
Merck has managed to beat its first-quarter earnings expectations, and handily at that.
Pfizer Dodges a Bullet on Earnings
Pfizer has reported better-than-expected first-quarter earnings and revenue and offered guidance.
What to Expect From Merck and Pfizer Earnings
Pharmaceutical giants Merck and Pfizer are both releasing their first quarter financial results early Tuesday.
Key Analyst Sees Nearly 30% Upside in Ironwood
Merrill Lynch brings another company to the forefront that it considers a buy. Ironwood Pharmaceuticals is viewed favorably by the brokerage firm, with nearly 30% upside.
A Real Heartbreak for Celladon
Celladon announced negative results in clinical trial and shares plunged 80% Monday morning.
Short Sellers Become More Wary of Big Biotech
The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Will Biogen Earnings Interrupt the Biotech Bull Market?
Biogen reported disappointing first-quarter financials before the markets opened Friday.
GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation
A late day call on Thursday from Bank of America Merrill Lynch took GW Pharmaceuticals' share price target far higher.
Amgen Earnings Point to More Froth in the Biotech Sector
Amgen reported better-than-expected first-quarter 2015 earnings Tuesday afternoon after equity markets had closed.
Will Amgen Earnings Shape Biotech for the Rest of 2015?
After markets close on Tuesday, Amgen, the second-largest biotech, is scheduled to announce its first-quarter results.